Evidence map›Paper›PMID 35112242›Full record

ReviewCurrent cardiology reports2022

Is There a Role for Triple Therapy After ACS?

Sukhdeep Bhogal, Mohamad Alkhouli, Christopher J White, Steven Bailey, Mamas Mamas, Elias Haddad, Timir K Paul

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Sukhdeep BhogalMedstar Washington Hospital Center, Washington, DC, USA.
Mohamad AlkhouliDepartment of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
Christopher J WhiteDepartment of Cardiovascular Diseases, The Ochsner Clinical School, Ochsner Medical Center, University of Queensland, AU, John Ochsner Heart & Vascular Institute, New Orleans, LA, USA.
Steven BaileyLousiana State University-Shreveport, Shreveport, LA, USA.
Mamas MamasKeele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Stoke-on-Trent, UK.
Elias HaddadUniversity of Tennessee at Nashville, 4230 Harding Pike, Nashville, TN, 37025, USA.
Timir K PaulUniversity of Tennessee at Nashville, 4230 Harding Pike, Nashville, TN, 37025, USA. tpaul5@uthsc.edu.
University of Tennessee at Martin · USKeele University · GBLouisiana State University in Shreveport · USMayo Clinic in Arizona · USMedStar Washington Hospital Center · USOchsner Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe optimal antithrombotic strategy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains the subject of controversy. In this article, we review the current evidence for the use of triple therapy in acute coronary syndrome (ACS) patients. RECENT

findingsThe recently published trials of AF patients undergoing PCI have shown that combination of non-vitamin K oral anticoagulants (NOACs) with an antiplatelet agent is either superior or non-inferior to vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) in reducing bleeding complications with no difference in regard to thromboembolic events. Currently, the use of dual therapy (preferably with a NOAC and clopidogrel) is recommended over triple therapy in these patients. The optimal duration should be guided by the assessment of an individual's risk of thrombosis and bleeding events.

Indexed as

Acute Coronary SyndromeAtrial FibrillationPercutaneous Coronary InterventionAdministration, OralAnticoagulantsDrug Therapy, CombinationFibrinolytic AgentsHumansPlatelet Aggregation InhibitorsAnticoagulantsFibrinolytic AgentsPlatelet Aggregation InhibitorsAcute coronary syndromeAtrial fibrillationDual therapyNon-vitamin K oral anticoagulantsTriple therapyVitamin K antagonist

Identifiers

PMID35112242
OpenAlexW4210592929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.